pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GLP-1 receptor · news · pharmadog
← back to GLP-1 receptor
News · GLP-1 receptor
471
stories
18d
With MFN now embedded in pharma, execs see little impact from Democrats’ blue wave
biospace
18d
Novo, Lilly battle for oral GLP-1 dominance with data tit for tat
biospace
18d
Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review
biospace
18d
Novo forecasts flat 2026 sales as finance chief departs
endpoints
18d
Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
fiercebiotech
19d
Pfizer, fresh to China’s obesity market, looks to Viagra model to compete
biospace
19d
Pfizer pares back obesity pipeline, drops phase 2-stage lung disease candidate
fiercebiotech
23d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
23d
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
biopharma dive
24d
For Lilly, cash-pay is key in the US and, increasingly, abroad
endpoints
24d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
24d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
24d
Lilly again far surpasses revenue expectations
endpoints
24d
Ascletis’ challenger to Lilly’s Foundayo hits goals in phase 2 diabetes trial
fiercebiotech
25d
Oura, UC San Diego Health collaborate to study GLP-1 outcomes using continuous smart ring data
fiercebiotech
25d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
25d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
25d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
25d
5 new drug launches that defied industry expectations
biospace
26d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
27d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
27d
Corxel claims oral obesity drug is in the ‘right lane’ as biotech plans SPAC route to Nasdaq
fiercebiotech
27d
Corxel to take oral GLP-1 public in the US via SPAC
endpoints
Oct 23, 26
Roche flags ‘final opportunity’ for Germany to reestablish as a reliable investment location
biospace
Oct 23, 26
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns
biospace
Oct 22, 26
STAT+: Will the Treasury restrict U.S. investment in the Chinese biotech sector?
stat
Oct 22, 26
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
Oct 22, 26
Big trials push beyond obesity to see if GLP-1s can quell alcohol, drug cravings
endpoints
Oct 22, 26
STAT+: Pharmalittle: We’re reading about a U.S. rule on Chinese deals, Belgium refusing Mounjaro coverage, and more
stat
Oct 22, 26
Health insurance premiums jump 9%, and more Americans don’t have access to coverage
stat
← prev
page 3 of 16
next →